-
1 month ago | 
nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more
AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.
-
Feb 19, 2025 | 
nature.com | George Duran |David Miklos |Surbhi Sidana |Mia Carleton |Alisha M. Maltos
AbstractDespite advances in treatments, multiple myeloma (MM) remains an incurable cancer where relapse is common. We developed a circulating tumor DNA (ctDNA) approach in order to characterize tumor genomics, monitor treatment response, and detect early relapse in MM. By sequencing 412 specimens from 64 patients with newly diagnosed or relapsed/refractory disease, we demonstrate the correlation between ctDNA and key clinical biomarkers, as well as patient outcomes.
-
Nov 15, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
November 15, 2024By Panelists discuss effective strategies for promoting the adoption of bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM) treatment, emphasizing the importance of educational initiatives, improving care transitions between academic and community settings, addressing misconceptions, and sharing key takeaways and clinical pearls for community oncologists.
-
Nov 8, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
November 8, 2024By Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).
-
Nov 1, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
November 1, 2024By Panelists discuss the rationale behind combination strategies with bispecifics in relapsed/refractory multiple myeloma (R/R MM), highlighting key studies such as RedirecTT-1 for teclistamab and talquetamab, TRIMM-2 for talquetamab and daratumumab, and MagnetisMM-32 for elranatamab, along with considerations for step-up dosing and outpatient administration protocols.
-
Oct 25, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
Management of Relapsed/Refractory Multiple Myeloma with Bispecifics: MonumenTAL-2, MajesTEC-1, and MagnetisMM-3 trialsPanelists discuss recent updates in the management of relapsed/refractory multiple myeloma, focusing on key studies such as MonumenTAL-2 for talquetamab, long-term follow-up data from the phase 1/2 MajesTEC-1 for teclistamab, and findings from MagnetisMM-3 regarding elranatamab.
-
Oct 18, 2024 | 
cancernetwork.com | Saad Usmani |Rafael Fonseca |Surbhi Sidana |Ajay K. Nooka
October 18, 2024By Panelists discuss how the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM) includes standard options like such as IMiDs, PIs, and mAbs, while highlighting the emergence of novel therapies such as CAR T- cells and bispecific antibodies, which address unmet needs and offer potential advantages in treatment efficacy and patient outcomes. Video content above is prompted by the following:Provide an overview of the current treatment landscape for R/R MM.
-
Sep 3, 2024 | 
cancernetwork.com | Surbhi Sidana
CAR T-cell therapies, BCMA and GPRC5D bispecific antibodies, and cereblon E3 ligase modulators (CELMoDs) all have the potential to impact clinical practice for multiple myeloma, according to Surbhi Sidana, MD.
-
Sep 1, 2024 | 
cancernetwork.com | Surbhi Sidana
CancerNetwork® spoke with Surbhi Sidana, MD, associate professor and hematologist of the Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University, and vice chair of the American Society of Hematology’s Committee on Communications, about the results from the phase 1/2 LINKER-MM1 trial (NCT03761108) published in the Journal of Clinical Oncology, in which investigators assessed the efficacy and safety of linvoseltamab in patients diagnosed...
-
Aug 31, 2024 | 
cancernetwork.com | Surbhi Sidana
Following treatment with linvoseltamab, BCMA bispecific antibodies, or immunotherapies, aggressive supportive care may be imperative to prevent high-grade infection occurrence, according to Surbhi Sidana, MD.
